Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children

2.50
Hdl Handle:
http://hdl.handle.net/10757/337985
Title:
Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
Authors:
Mezones Holguín, Edward ( 0000-0001-7168-8613 ) ; Bolaños Díaz, Rafael; Fiestas, Víctor; Sanabria, César; Gutiérrez Aguado, Alfonso; Fiestas, Fabián; Suárez, Víctor J.; Rodríguez Morales, Alfonso J.; Hernández, Adrian V. ( 0000-0002-9999-4003 )
Citation:
Mezones-Holguín E, Bolaños-Díaz R, Fiestas V, Sanabria C, Gutiérrez-Aguado A, Fiestas F, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children. The Journal of Infection in Developing Countries [Internet]. 15 de diciembre de 2014 [citado 8 de enero de 2015];8(12). Recuperado a partir de: http://www.jidc.org/index.php/journal/article/view/25500653
Publisher:
The Journal of Infection in Developing Countries
Journal:
The Journal of Infection in Developing Countries (J Infect Dev Ctries)
Issue Date:
8-Jan-2015
URI:
http://hdl.handle.net/10757/337985
Additional Links:
http://www.jidc.org/index.php/journal/article/view/25500653
Abstract:
Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 yearsold. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
Description:
emezones@gmail.com
Keywords:
Pneumococcal; Pneumococcal vaccines; Cost-effectiveness; Immunization programs; Peru; Pneumonia
ISSN:
2036-6590
EISSN:
1972-2680

Full metadata record

DC FieldValue Language
dc.contributor.authorMezones Holguín, Edwardes_PE
dc.contributor.authorBolaños Díaz, Rafaeles_PE
dc.contributor.authorFiestas, Víctores_PE
dc.contributor.authorSanabria, Césares_PE
dc.contributor.authorGutiérrez Aguado, Alfonsoes_PE
dc.contributor.authorFiestas, Fabiánes_PE
dc.contributor.authorSuárez, Víctor J.es_PE
dc.contributor.authorRodríguez Morales, Alfonso J.es_PE
dc.contributor.authorHernández, Adrian V.es_PE
dc.date.accessioned2015-01-08T21:03:06Zes_PE
dc.date.available2015-01-08T21:03:06Zes_PE
dc.date.issued2015-01-08es_PE
dc.identifier.citationMezones-Holguín E, Bolaños-Díaz R, Fiestas V, Sanabria C, Gutiérrez-Aguado A, Fiestas F, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children. The Journal of Infection in Developing Countries [Internet]. 15 de diciembre de 2014 [citado 8 de enero de 2015];8(12). Recuperado a partir de: http://www.jidc.org/index.php/journal/article/view/25500653es_PE
dc.identifier.issn2036-6590es_PE
dc.identifier.urihttp://hdl.handle.net/10757/337985es_PE
dc.descriptionemezones@gmail.comes_PE
dc.description.abstractIntroduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 yearsold. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.eng
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherThe Journal of Infection in Developing Countrieses_PE
dc.relation.urlhttp://www.jidc.org/index.php/journal/article/view/25500653es_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectPneumococcales_PE
dc.subjectPneumococcal vaccineses_PE
dc.subjectCost-effectivenesses_PE
dc.subjectImmunization programses_PE
dc.subjectPerues_PE
dc.subjectPneumoniaes_PE
dc.titleCost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian childrenes_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.eissn1972-2680es_PE
dc.identifier.journalThe Journal of Infection in Developing Countries (J Infect Dev Ctries)es_PE
dc.description.fundingThis study was funded by Instituto Nacional de Salud, Lima, Perueng
dc.description.peer-reviewRevisión pór pareses_PE
This item is licensed under a Creative Commons License
Creative Commons
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.